SERDs (estrogen receptor degraders) clinical trials
A class of medicines: the studies that test any of its 7 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones. In MeSH: Estrogen Receptor Antagonists.
Get an email when these change. Save the serds (estrogen receptor degraders) studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Medicines in this class
Studies that test each. A study of two counts under both, and once above.
Studies by the year they started
235 studies that test it; most in 2023 (27)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1998 | 1 |
| 2000 | 2 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 14 |
| 2005 | 5 |
| 2006 | 7 |
| 2007 | 7 |
| 2008 | 5 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 7 |
| 2015 | 8 |
| 2016 | 5 |
| 2017 | 10 |
| 2018 | 7 |
| 2019 | 10 |
| 2020 | 13 |
| 2021 | 18 |
| 2022 | 23 |
| 2023 | 27 |
| 2024 | 15 |
| 2025 | 13 |
| 2026 | 23 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 112 · Other 123
AstraZeneca (38) · Pfizer (19) · Eli Lilly and Company (13) · Hoffmann-La Roche (11) · Stemline Therapeutics, Inc. (9) · Genentech, Inc. (6) · MedSIR (4) · Olema Pharmaceuticals, Inc. (4)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing one of them · 235
- A Study of Imlunestrant (LY3484356) in Healthy Female ParticipantsNot yet recruitingPhase 1Eli Lilly and CompanyNCT07918859Written as Imlunestrant (Test)
- A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast CancerRecruitingPhase 2Stemline Therapeutics, Inc.NCT07766018Written as Elacestrant
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast CancerRecruitingPhase 2Eli Lilly and CompanyNCT07287098Written as Imlunestrant
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as Giredestrant
- A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During TreatmentRecruitingPhase 3Hoffmann-La RocheNCT07827573Written as Giredestrant
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT06380751Written as Camizestrant
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT06075953Written as Elacestrant
- A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruitingPhase 2Hoffmann-La RocheNCT07054190Written as Giredestrant
- A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)RecruitingPhase 3Genentech, Inc.NCT07541079Written as Giredestrant
- A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingPhase 3AstraZenecaNCT07647328Written as Camizestrant
- Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingPhase 2University of California, IrvineNCT05524584Written as Fulvestrant
- A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine TherapyRecruitingPhase 3AstraZenecaNCT05774951Written as Camizestrant
- Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast CancerRecruitingPhase 1/2Stemline Therapeutics, Inc.NCT05386108Written as Elacestrant
- Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)RecruitingPhase 3European Organisation for Research and Treatment of Cancer - EORTCNCT05512364Written as Elacestrant
- Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in MalesRecruitingPhase 1Northwestern UniversityNCT07604272Written as Fulvestrant
- Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast CancerRecruitingPhase 2AstraZenecaNCT07427394Written as Camizestrant
- Phase II Study of CAmizestrant in Resectable Endometrial AdenocarcinomaNot yet recruitingPhase 2University Health Network, TorontoNCT07840443Written as Camizestrant
- Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerRecruitingPhase 3Olema Pharmaceuticals, Inc.NCT07085767Written as Palazestrant
- Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07832227Written as Imlunestrant
- Circulating Tumor DNARecruitingPhase 2Yale UniversityNCT06923527Written as Elacestrant
See all 235 studies that test one of the serds (estrogen receptor degraders) →